title: Amoxycillin/clavulanic acid ('Augmentin') compared with a combination of aminopenicillin, aminoglycoside and metronidazole in the treatment of pelvic inflammatory disease.
abstract: A randomized, multi-centre trial was carried out in 152 hospitalized women with pelvic inflammatory disease to evaluate the efficacy and tolerability of amoxycillin/clavulanic acid compared with that of a standard regimen using three antimicrobial agents (aminopenicillin, an aminoglycoside and metronidazole). Seventy patients initially received 3 to 4 intravenous doses per day of 1 g amoxycillin/200 mg clavulanic acid (mean 7.7 days) and then 4 to 6 tablets per day of 500 mg amoxycillin/125 mg clavulanic acid (mean 11.2 days). The other group of 82 patients initially received parenteral therapy daily (mean 7.7 days) with a combination of 3 to 4 g amoxycillin or ampicillin, 160 mg gentamicin (or 150 mg dibekacin or tobramycin) and 1.5 g metronidazole, and then oral therapy with 2 to 3 g amoxycillin or ampicillin and 1 to 1.5 g metronidazole daily (11.1 days). Clinical results, assessed at discharge from hospital (mean 10 days in both groups), were comparable in both groups, with 96% complete or partial response and no failures in the amoxycillin/clavulanic acid group, and 90% complete or partial successes and 5 failures with the triple therapy regimen. Both treatments were well tolerated and very few side-effects were reported.
authors.affiliation: Hôpital Lariboisière, Paris, France.
authors.forename: N
authors.initials: N
authors.lastname: Cirau-Vigneron
authors.forename: J
authors.initials: J
authors.lastname: Barrier
authors.forename: J
authors.initials: J
authors.lastname: Becue
authors.forename: M
authors.initials: M
authors.lastname: Chartier
authors.forename: J R
authors.initials: JR
authors.lastname: Giraud
authors.forename: P
authors.initials: P
authors.lastname: Landes
authors.forename: J
authors.initials: J
authors.lastname: Leng
authors.forename: D
authors.initials: D
authors.lastname: Raudrant
authors.forename: J M
authors.initials: JM
authors.lastname: Reme
mesh_terms: D000328:Adult; D000617:Aminoglycosides; D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019980:Amoxicillin-Potassium Clavulanate Combination; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy*; D010406:Penicillins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D010406:Penicillins; D008795:Metronidazole; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin